Investors in Aquestive Therapeutics Face Challenges After Major Price Target Cut

Concerns for Investors in Aquestive Therapeutics

On January 9, 2026, a significant shift occurred for investors in Aquestive Therapeutics, Inc. (NASDAQ: AQST) when Cantor Fitzgerald lowered its price target from $15 to $8, signaling a growing unease regarding the company's future. The downgrade, which reflected a drop of around 47%, was attributed to increased risks associated with the FDA's evaluation of the company's product Anaphylm.

Impact of the Downgrade

This sharp decline in price target has alarming implications for shareholders of AQST who had already experienced substantial losses. Following the announcement, the stock plummeted from $6.21 to $3.91 per share, marking a staggering decrease of $2.30 in a single trading session. The FDA's communication regarding deficiencies in the New Drug Application (NDA) for Anaphylm has triggered concerns about prolonged delays in the approval process. The ongoing saga has left shareholders reeling, as many saw their investment value diminish by over 37% following this critical disclosure.

Analyst Expectations vs. Reality

During the period leading up to the downgrade, analysts had painted an optimistic picture of AQST's prospects. They based their projections on the company’s assurances that Anaphylm was on track for FDA approval by January 31, 2026. However, this optimism quickly turned to pessimism as it became apparent that the company had misrepresented the state of its FDA review. Management characterized the review process as routine, assuring investors of impending approvals, only for the FDA to later reveal significant deficiencies that led to a halt in discussions about product labeling.

In light of these developments, analysts have had to rapidly revise their expectations. Oppenheimer, another major player in the investment community, noted that the factors surrounding the Anaphylm NDA indicated a meaningful setback, and suggested that the stock was now pricing in a worst-case scenario—potentially dropping to as low as $1 per share depending on future communications from the FDA.

The Broader Implications for Investors

Analyzing this series of events, attorney Joseph E. Levi warns that the rapid and large-scale downgrades from analysts underscore the negative impact that misleading company disclosures can have on investors. Many investors are left to grapple with the substantial losses stemming from this unexpected turn of events. The downgrades issued by key analysts have highlighted the material nature of management's statements regarding the FDA review process.

For investors who lost money on AQST shares, the deadline for filing as lead plaintiff in a potential class action lawsuit has been set for May 4, 2026. Shareholders who purchased AQST securities between June 16, 2025, and January 8, 2026, are encouraged to seek legal counsel to explore their options for recovering losses.

Conclusion

As the situation continues to evolve, the case of Aquestive Therapeutics serves as a cautionary tale about the risks inherent in the pharmaceutical sector, particularly regarding FDA reviews and investor communications. The dichotomy between management's assurances and the FDA's eventual findings has left many investors questioning their trust in company leadership, highlighting the need for transparency in communications with shareholders. Investors who engaged in trading prior to the January announcement can potentially benefit from taking legal action to recoup their investments in light of the unfolding circumstances.